To evaluate if myeloid BTK can predict survival in human NB, we used publicly available R2 Genomics and Visualization platform (http://r2.amc.nl, accessed on 16 February 2021) and analyzed the expression of BTK and monocyte marker CD14 in four different datasets (cohort 1, Versteeg N = 88; cohort 2, Delattre N = 64; cohort 3, Latowska N = 30; cohort 4, Hiyama N = 51). This evidence concerns the gene BTK and neuroblastoma.